• To the text
  • To main menu
  • To header menu
  • To footer menu

Taisho Pharmaceutical Holdings

Search
Search
MENU
  • Who We Are

    Who We Are

    Who We Are

    • Who We Are Overview
    • At a Glance
    • Message from Management
    • History
    • Philosophy
    • Board Members
    • Worldwide Locations
  • Our Products

    Our Products

    Our Products

    • Our Products Overview
    • Lipovitan Series
    • Pabron Series
    • RiUP Series
    • Counterpain®
    • Tempra®
    • Hapacol
    • Dafalgan®
    • Efferalgan®
  • Investors

    Investors

    Investors

    • Investors Overview
    • Our Business
    • Financial Highlights
    • Segment Information
    • Financial Results
    • Presentations
    • Annual Reports
    • Stock Information
  • Sustainability

    Sustainability

    Sustainability

    • Sustainability Overview
    • Sustainability Policy
    • Environment
      • Sustainability
      • Environment
      • Environment Overview
      • Policies for Environmental Activities
      • Environmental Management
      • Environmental Accounting
      • Impact of Corporate Activities
      • Objectives and Achievements
      • Addressing Climate Change
      • Resource Recycling
      • Pollution Control
      • Community Initiatives
      • Methods and Data
      • Environmental Reports
    • Social
      • Sustainability
      • Social
      • Social Overview
      • Customers
      • Business Partners
      • Employees
      • Society
    • Governance
      • Sustainability
      • Governance
      • Governance Overview
      • Corporate Governance
      • Internal Control
      • Compliance
      • Risk Management
  • News
  • Contact Us
  • Home
    • Who We Are
    • Our Products
    • Investors
    • Sustainability
  • Sitemap

Sitemap

Who We Are

  • At a Glance

  • Message from Management

  • History

  • Philosophy

  • Board Members

  • Worldwide Locations

Our Products

  • Lipovitan Series

  • Pabron Series

  • RiUP Series

  • Counterpain®

  • Tempra®

  • Hapacol

  • Dafalgan®

  • Efferalgan®

Investors

  • Our Business

  • Financial Highlights

  • Segment Information

  • Financial Results

  • Presentations

  • Annual Reports

  • Stock Information

Sustainability

Sustainability Policy

Environment

  • Policies for Environmental Activities
  • Environmental Management
  • Environmental Accounting
  • Impact of Corporate Activities
  • Objectives and Achievements
  • Addressing Climate Change
  • Resource Recycling
  • Pollution Control
  • Community Initiatives
  • Methods and Data
  • Environmental Reports

Social

  • Customers
  • Business Partners
  • Employees
  • Society

Governance

  • Corporate Governance
  • Internal Control
  • Compliance
  • Risk Management

News

Contact Us

Privacy

Site Policy

Web Accessibility

  • Privacy
  • Site Policy
  • Web Accessibility
  • Sitemap

Taisho Pharmaceutical Holdings (Japanese)

© Taisho Pharmaceutical Holdings Co., Ltd. All Rights Reserved. 

Back to top